Stručni rad

Dasatinib in treatment of Ph+ CML – Zagreb experience

Dubravka Sertić ; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Sanja Davidović ; Klinički zavod za laboratorijsku dijagnostiku, KBC Zagreb, Zagreb, Hrvatska
Renata Zadro ; Klinički zavod za laboratorijsku dijagnostiku, KBC Zagreb, Zagreb, Hrvatska
Igor Aurer ; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Boris Labar ; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska

Sažetak

Aim: We report the treatment outcome of dasatinib therapy for Philadelphia positive chronic myeloid leukemia (Ph+ CML) in patients who were previously treated with imatinib. Metodhs: Eight out of 11 patients with Ph+ KML in chronic phase received dasatinib 100 mg/day. For patients in blastic crysis (3 patients) the dose of dasatinib was 140 mg/day. Results: In 8 patients in chronic phase complete hematologic response was achieved; 7 of them showed complete cytogenetic response while major molecular response was documented in 6 patients. In 3 patients with blastic transformation, after a short clinical and hematological response, the signs of blastic crisis was proved after 5, 7 and 8 months. In all of them T315I mutation was documented. Dasatinib therapy was feasible. In one patient pleural effussion grade 2 developed, while in one patient because of lower number of platelet the dose of dasatinib had to be decreased. Discussion and conclusion: Dasatinib is very effective in the treatment of Ph+ CML after the imatinib treatment failure. Adverse events were not severe. Treatment was not stopped because of nonhematological adverse events. In patients with blastic transformation treatment control of CML is temporary which allows time to find a suitable bone marrow donor and treatment with allogeneic transplantation.

Ključne riječi

dasatinib; Ph+ chronic myeloid leukemia; second line therapy

Hrčak ID:

76673

URI

https://hrcak.srce.hr/76673

Datum izdavanja:

1.12.2011.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.924 *